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Abstract
Recent studies have demonstrated a relationship between the severe clinical course of COVID-19 and other chronic
diseases such as: cardiovascular disease, hypertension, diabetes mellitus, obesity and chronic renal disease. It may
be possible to extend this association to a common and chronic oral disease in adults: periodontitis. Alternatively,
the latter could be simply related to the systemic chronic diseases cited above, as already observed in the non-
COVID-19 literature. In order to provide an overview and their opinion, the authors in this perspective article will
report and discuss the most recent references of interest relating to COVID-19 and periodontitis pathophysiology.
Within such a narrative review, the authors will hypothesize that the association between chronic periodontitis and
COVID-19 could exist via two pathways: a direct link, through the ACEII and CD147 receptors used by the virus to
infect the cells, which would occur in greater numbers in cases of periodontitis (thereby favoring a SARS-CoV-2
infection); and/or an indirect pathway involving the overexpression of inflammatory molecules, especially IL-6 and
IL-17. An expression of the latter has been found to play a role in periodontitis, in addition to severe cases of
COVID-19, although it is still unclear if it plays a direct role in the worsening of the clinical course.
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Introduction
Coronavirus disease 2019 (COVID-19), due to SARS-CoV-
2, is the most pressing and emergent health problem world-
wide. While most cases result in mild symptoms (including
hyposalivation and an alteration in taste [1]), some cases
progress to severe pneumonia and multi-organ failure with
the death of the patient, according to the age and the
presence of comorbidities [2]. Recent relevant studies have
demonstrated the bidirectional association between the
severe clinical course of COVID-19 and chronic diseases
such as: cardiovascular disease, hypertension, diabetes
mellitus, obesity and chronic renal disease [1, 3–5]. In
seeking a link between COVID-19 and these chronic dis-
eases, they are garnering worldwide interest in the field of
research. This interest may also be extended to include
more common, chronic oral diseases in adults, such as peri-
odontitis [6], with already demonstrated correlations and
associations with other chronic diseases, as mentioned
above [7]. The authors in this perspective article will report
the most recent references of interest regarding COVID-19
and periodontal physiopathology in order to improve our
understanding of associated or randomly associated factors.
Data from the literature [8–12] has confirmed that the
majority of COVID-19 positive patients are male. And
male sex was observed to be an independent risk factor,
which was associated with refractory disease and death
(2.8 % death rate for men vs. 1.7 % for female) [11, 13].
With reference to the hypothesis in this article concern-
ing the association between periodontal pathophysiology
and COVID-19, let us begin with the argumentation of
the studies showing that SARS-CoV-2 also enters the
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human body via the oral mucosa [1, 14] through the
Angiotensin Converting Enzyme II (ACE2) receptor
[15–17], which is highly expressed in the oral mucosa
(mostly in the epithelial cells of the tongue) [16, 18] and
in the salivary glands [5].
A study by Pascolo et al. has demonstrated the neces-
sary co-expression of ACE2 and trans-membrane serine
protease (TMPRSS2), to enable the entry of SARS-CoV-
2 into host cells [19]. Indeed, the TMPRSS and furin
serve to cleave the virus S protein and thereafter spread
the infection [20]. Recently, preliminary data has specu-
lated a new infection route for SARS-CoV-2, in which
this virus could use its spike protein to bind to CD147
in order to infect human cells [21]. In support of the hy-
pothesis outlined in this article, this would, therefore, re-
sult in a high expression of CD147 in the epithelial cells,
particularly those of the oral mucosa [22, 23]. Additional
data lending credence to the speculation in this article is
that SARS-CoV-2 resides in saliva and nasopharynx in
such quantities so as to render swabs with these samples
useful for COVID-19 diagnostic tests [24–26]. Further-
more, a recent study by Gupta et al. has demonstrated
the presence of SARS-CoV-2 in gingival crevicular fluid
(GCF), with a sensitivity of the diagnostic swab of
63.64 % (a salivary swab has a sensitivity of approxi-
mately 64 %) [24]. Hence, the fact that SARS-CoV-2
stagnates in the GCF may lead us to conclude that poor
oral hygiene may increase the viral load in the oral
cavity.
Two possible mechanisms which could explain the
association between periodontitis and the COVID-19
disease are: (1) the direct contact of virus with the
periodontal tissues, also due to the high expression of
ACEII and CD147, as mentioned above; and/or (2) the
similar overexpression of several cytokines, a COVID-19
‘cytokine storm’, with elevated serum levels of IL-1 beta,
IL-6, IL-7, IL-10, IL-17, IL-2, IL-8, IL-9, GM-CSF, G-
CSF, IFN-gamma, TNF alpha, MIP1A, MIP1B, MCP1
and IP10 [27, 28].
In this regard, the authors of this article have analysed
the literature data concerning IL-6 and IL-17, which is
also overexpressed in periodontitis [29]. Several studies
have suggested the role of IL-6 in the pathogenetic
mechanisms of COVID-19 [30–35]: when SARS-CoV-2
infects the respiratory tract, it induces a release of pro-
inflammatory cytokines, including interleukin (IL)-1beta
and IL-6 [31]. One of the mechanisms making the
coronavirus lethal could be the induction of interstitial
pneumonia, which is in turn linked to an over-
production of IL-6 [34, 36]. Similarly, IL-17 has high
levels in the serum of COVID-19 patients [27]. In a re-
cent study, an increase in IL-17, and 14 other cytokines,
levels were positively correlated with a higher Murray
score for lung injuries [28]. Notwithstanding this, some
authors have hypothesized that the role of IL-6 merely
serves as a reliable biomarker for the early detection and
progression of COVID-19 [37]. Periodontal disease has
also been recognized as a cytokine storm-generating
disease, especially in the presence of other chronic dys-
metabolic diseases, such as diabetes [12, 38–40]. Indeed,
diabetes can cause a chronic activation of the immune
system with increased levels of circulating leukocytes
and pro-inflammatory markers [41]; these include serum
levels of inflammation-related biomarkers such as IL-6,
C-reactive protein, serum ferritin and the D-dimer
coagulation index [42].
Focus on periodontitis
Periodontitis (i.e. plaque-related periodontal disease) is
defined as “a chronic, multifactorial inflammatory
disease, associated with dysbiotic plaque biofilms and
characterized by the progressive destruction of the
tooth-supporting apparatus” [43, 44], and classified by
staging and grading systems [45]. The disease of
periodontitis is globally widespread: in China it has been
estimated that the prevalence of the severe variant is
1.9 %, and that those with diabetes are 2.4 times more
likely to possess this variant [46]. In recent years there
has been particular interest in probable associations
between periodontal infection and systemic diseases
[38]. Indeed, periodontal pathogens and their products
(including inflammatory mediators such as IL-6) could
enter the bloodstream, thereby causing several systemic
diseases. Chronic periodontitis has been shown to be a
risk factor for: cardiovascular disease, diabetes mellitus,
respiratory disease, rheumatoid arthritis and other
conditions [38]. Indeed, periodontopathic bacteria were
found in the bronchoalveolar lavage fluid of patients
suffering from pneumonia [47]. In turn, diabetes could
increase the risk of developing pneumonia [42, 48, 49]
and, thus, the association of periodontitis and diabetes
could multiply the risk of pneumonia even in the ab-
sence of the SARS-CoV-2 infection [1, 50].
It is of note that periodontitis has a documented,
higher prevalence in men (~ 57 %) as compared to
women (~ 39 %), thereby signifying a possible sex in-
volvement in disease pathogenesis [51]. Furthermore,
there are several microbial exchanges (primarily S.
mutans, P. intermedia, F. nucleatum and P. gingivalis)
between the oral cavity and the lungs [52, 53], and tooth
decay and periodontitis are the oral diseases which are
predominantly involved in oral bacterial disequilibrium
[54]. In order to explain these exchanges (and, therefore,
respiratory infections), two hypotheses have been pro-
posed; (1) cytokines and enzymes produced during a
periodontal disease may alter the respiratory epithelium
and oral mucosa, thereby favoring infection; and (2) the
aspiration of oral pathogens into the lungs [55]. Thus,
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poor oral hygiene can increase the risk of such mouth-
lung exchanges and, therefore, respiratory infections,
especially in patients over the age of 70 [56, 57].
A previous study has shown that there was an increase
in IL-17-producing cells in the gingival tissue of patients
suffering from gingivitis and periodontitis, as compared
to healthy controls [58]. The same authors reported have
elevated levels of IL-17 in the serum of patients with
periodontal disease [58]. The systemic inflammatory
burden of periodontitis is also well-documented by
virtue of the presence of the marked sensitivity of the C-
reactive protein (hsCRP), a component of positive Acute
Phase Proteins (APPs), which increase during a phlogis-
tic process [58–60]. Indeed, there is evidence regarding
increased levels of chemokine- and cytokine-producing
cells in the epithelium of periodontopathic patients, and
increased levels of these inflammatory markers in the
serum of the same patients [61, 62]. Another positive
APP is Galectin-3 (Gal-3), a pro-inflammatory protein
which is involved in several mechanisms such as: inflam-
mation, angiogenesis, cell growth, host defence and others
[63]. Moreover, elevated levels of Gal-3 are related to
severe periodontitis [62]. Finally, a correlation between
Gal-3 and SARS-CoV-2 was observed in a recent study in
which the morphology of Gal-3 was observed to be similar
to the SARS-CoV-2 spike protein [64–67].
Perspective hypothesis: is there any association
between COVID-19 and periodontitis?
Basing our hypotheses on the most recent literature and,
therefore, on that which has been definitively demon-
strated for periodontitis, several events would seem to
correlate with the clinical behavior of COVID-19 with a
patient’s periodontal status. By causing ulceration of the
gingival epithelium, periodontitis could reduce the
protective function of the oral epithelial cells, thereby
exposing the patients to an elevated risk of invasion by
SARS-CoV-2 [1]. Concurrently, ACE2, TMPRSS2 and
furin, which are expressed in the aforementioned oral
epithelial cells and the proteases produced by periodon-
topathic bacteria, could cleave the protein S of the virus,
thereby favoring infection. It, therefore, follows that the
presence of periodontopathic bacteria could increase the
risk of SARS-CoV-2 infection [68].
Various studies have shown that the oral, subgingival-
component epithelial cells of periodontal pockets express
high levels of CD147 [22, 23] and thus, periodontitis could
facilitate SARS-CoV-2 infection through the CD147 route.
Takahashi Y et al., have argued (with their unpublished
data) that, when periodontopathic bacteria are aspirated
into the lungs, the expression of ACE2 increases in the
bronchus and the lungs (also in the oral cavity) due to
bacterial and pathogenic factors, such as endotoxins, and
that this overexpression could increase the risk of a
SARS-CoV-2 infection [68].
In a recent study by Takahashi Y et al., the culture
supernatant of the periodontopathic bacterium Fusobac-
terium nucleatum (CSF) has been shown to upregulate
the angiotensin converting enzyme 2 of the SARS-CoV-
2 receptor in alveolar epithelial cells [69]. Furthermore,
CSF induced the production of interleukin (IL) -6 and
IL-8 by alveolar epithelial cells; CSF also strongly in-
duced the expression of IL-6 and IL-8 by bronchial epi-
thelial cells of pharyngeal epithelial cells. These findings
suggest that when patients with mild COVID-19 fre-
quently aspirate periodontopathic bacteria, SARS-CoV-2
infection is promoted, and lower respiratory tract in-
flammation can become severe in the presence of viral
pneumonia [69].
Moreover, Marouf N et al., in a case-control study,
demonstrated that periodontitis was associated with
higher risk of intensive care unit admission, need for
assisted ventilation and death of COVID-19 patients,
and with increased blood levels of biomarkers linked to
worse disease outcomes [70].
Other researchers have hypothesized that, in a given
patient with periodontal disease the periodontal situation
during a SARS-CoV-2 infection could be aggravated due
to the downregulation of ACE2 and an increase in ACE
and Ang II, thereby resulting in the involvement of sev-
eral pro-inflammatory factors [71, 72]. It is also note-
worthy that periodontopathic bacteria have been found
in the metagenome of severe COVID-19 patients [73];
indeed, it is commonplace to find bacterial superinfec-
tions in patients with severe cases of COVID-19 [74].
It is clear that respiratory viral infections could predispose
patients to bacterial superinfections, resulting in increased
disease severity and mortality [75]. Indeed, strains of the
coronavirus have been shown to improve the adhesion of
streptococcus to epithelial cells of the respiratory tract,
causing complications such as pneumonia and inflamma-
tory damage in the lungs and consequent inhibition of the
clearance of bacteria [75]. Finally, a recent study has
demonstrated that intensive periodontal treatment reduced
the risk of pneumonia in COVID-19 patients [48].
Albeit indirect, another possible mechanism, which
could explain the association between periodontal dis-
ease and a severe COVID-19 course, could be the
overproduction of phlogistic molecules, such as IL-6 and
IL-17, in healthy patients and patients with chronic dis-
eases such as diabetes. It should be considered that peri-
odontitis, independently of any other pathology, raises
IL-6. Therefore and irrespective of the concept that IL-6
is the cause of severe cases of COVID-19 or a reliable
biomarker for COVID-19 [37], periodontitis could
modify the level of IL-6 in COVID-19 patients. It can
also be hypothesized that in those COVID-19 patients,
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also suffering from diabetes and periodontitis, levels of
IL-6 in circulation deriving from all three pathologies
could be envisaged.
Considering the aforementioned research, it is the
considered opinion of the authors of this perspective
article that it merits further discussion in encouraging
reflection and/or experimental studies in the following
fields: an analysis of the association and/or risk of
periodontitis in COVID-19/diabetic patients, who are at
greater risk of and developing both diseases; and to
ascertain whether the use of molecules against the S-
protein (and, therefore, against Gal-3, or vice versa)
could be useful in disrupting the attachment of the virus
to the host cells and indecreasing the production of IL-1
and IL-6.
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